glp 1 and migraines GLP-1 Drug Cuts Migraine Days in Half A new study finds that GLP-1 Medications and Migraine Headache

G49, a dual glucagon/glucagon-like peptide-1 receptor agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas and liver, leading to brown fat activation with the final outcomes of increased energy expenditure and body weight loss.

While effective, these treatments require monitoring due to potential side effects, especially in non-diabetic patients.This therapeutic advancement represents a revolution in the management of metabolic diseases and obesity.Despite their efficacy in managing obesity and metabolic disorders, GLP-1 and GIP receptor agonists can cause side effects, which are a common reason for therapy discontinuation

However, research suggests that a high protein diet and resistance training may help prevent loss of muscle mass during GLP- 1 RA usage

Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and